RU2570396C1 - Preparation "dioksomast" for treatment subclinical mastitis in cows - Google Patents

Abstract

FIELD: veterinary medicine.

SUBSTANCE: preparation comprises dioxidine, xanthan gum, lactam tetramethylenediethylenetetramine, distilled water, prednisolone in the following ratio of components, wt %: dioxidine - 1.0; xanthan gum - 0.18; lactam tetramethylenediethylenetetramine - 3.0; prednisolone - 0.7; distilled water - 95.12.

EFFECT: preparation is highly effective for treatment of subclinical mastitis in cows in lactation period and does not cause side effects in cows during treatment.

1 tbl, 1 ex

Description

The drug for the treatment of subclinical mastitis in cows during the lactation period

The invention relates to veterinary medicine, namely to the treatment of dysfunction of the mammary gland in cows.

A known drug for the treatment of mastitis in cows during the lactation period, which includes: dioxidine - 1.0%; xanthan gum - 0.18%; lactam tetramethylenediethylenetetramine - 3.0%; methyluracil - 0.5%; distilled water - 95.32% (RF patent No. 2491069, publ. 08.27.2013) [1].

A disadvantage of the known preparation is a side effect that occurs in some cows after its administration. The animal restlessly looks back at the udder, does not stand still and does not allow further treatment. This side effect is manifested due to the allergic reaction of some animals to the methyluracil (http://farmaspravka.com/metiluracil-methyluracil) that is part of the drug [2].

The objective of the invention is to remedy the above drawback.

The task is achieved due to the fact that the known drug for the treatment of subclinical mastitis in cows during the lactation period, containing dioxidine, xanthan gum, lactam tetramethylene diethylenetetramine, distilled water, according to the invention additionally contains prednisolone in the following ratio of components, mass. %: dioxidine - 1.0; xanthan gum - 0.18; lactam tetramethylenediethylenetetramine - 3.0; prednisone - 0.7; distilled water - 95.12.

The drug in appearance is a stable emulsion of light yellow color with a specific smell.

Dioxidin is a domestic synthetic antimicrobial drug with a wide spectrum of action (in relation to staphylococci, streptococci, meningococci, gram-negative bacteria, many anaerobes, as well as actinomycetes). The therapeutic efficacy is maintained on strains resistant to other antimicrobial agents. The drug is characterized by increased reaction properties, and also easily enters into redox reactions.

Lactam tetramethylenediethylenetetramine is able to penetrate into bacterial cells and viruses, interacting with the amino groups of purine and pyrimidine bases of nucleic acids, while blocking their matrix genetic function. The substance is not irritating to the mucous membranes.

Xanthan gum is a biopolymer that is able to stabilize solutions with good emulsifying properties. It forms a protective film on the surface, moisturizes the skin and does not have a harmful effect on the body.

Prednisolone is a synthetic medium strength glucocorticoid drug. It has anti-inflammatory, anti-allergic, anti-shock, immunosuppressive effects. It interacts with specific receptors in the cytoplasm of the cell and forms a complex that penetrates the nucleus of the cell, binds to DNA and causes the expression of mRNA, changing the formation of proteins on the ribosomes. It affects the alternative and exudative phases of inflammation and prevents the spread of the inflammatory process.

The inventive drug was used to treat subclinical mastitis in cows during the lactation period on milk production farms IP Koskina II, located in the Oryol region in the Bolkhov region.

Identification of sick cows with mastitis was carried out in accordance with the instruction "Instructions for the diagnosis, treatment and prevention of mastitis in cows (2000)." Subclinical mastitis was detected using a rapid mastitis test (BMT). Bacteriological studies of milk samples from sick cows isolated agalactic streptococcus, Staphylococcus aureus and Escherichia coli.

Scheme of setting the experience. Two groups of cows were selected, one was treated with a well-known drug, the other with the proposed drug.

Treatment with a famous drug. There were 10 cows in the group (16 shares of the udder were affected).

Treatment with the proposed drug. There were 12 cows in the group (20 shares of the udder were affected).

The treatment results are shown in the table.

After the evening milking of the cows before the administration of the drug, the secret is dispensed from the affected portion of the udder of the cow and disposed of, the nipple is disinfected. In the cold season, the drug bottle (or syringe tube) is heated to 37 ° C before use, shaken thoroughly until a uniform suspension is obtained. From the vial, the drug is collected in a sterile syringe 10 ml. The syringe is tightly pressed to the outer opening of the nipple canal, the drug is injected into the nipple cistern of the udder by gently pressing the syringe plunger. After the introduction of the drug, a light massage of the nipple of the affected lobe of the udder is conducted from the bottom up. The drug is administered twice, usually at a dose of 10 ml once a day after evening milking.

During treatment and during the day after the last injection of the drug, milk from the affected lobes of the udder is dispensed into a separate bowl, neutralized and disposed of. Of the remaining shares of the udder, milk is fed to animals after boiling (“Manual on the diagnosis, treatment and prevention of mastitis in cows” Approved by the Head of the Department of Veterinary of the Ministry of Agriculture of Russia on 30.03.03.).

The proposed preparation after introduction into the udder of cows did not cause side effects, unlike the known one, which caused an allergic reaction in the udder in 2 cows out of 10 animals.

In addition, when comparing the data obtained for the treatment of subclinical mastitis in cows with a known and proposed drug, it was found that the therapeutic effectiveness of the proposed drug is slightly higher than that of the known one.

When treating cows with the proposed drug in milk on the second day after treatment, inhibitory substances were not found.

Thus, the proposed drug for the treatment of subclinical mastitis in cows during the lactation period does not cause any side effects in cows during the treatment period.

Claims (1)

A drug for the treatment of subclinical mastitis in cows during the lactation period, containing dioxidine, xanthan gum, lactam tetramethylene diethylenetetramine, distilled water, characterized in that it additionally contains prednisolone in the following ratio of components, wt. %:
Dioxidine 1,0 Xanthan gum 0.18 Lactam tetramethylenediethylenetetramine 3.0 Prednisone 0.7 Distilled water 95.12